1. |
Perry MS. Don't fear the reefer-evidence mounts for plant-based cannabidiol as treatment for epilepsy. Epilepsy Curr, 2019, 19(2): 93-95.
|
2. |
Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patientswith treatment‐resistant epilepsy: an open‐label interventionaltrial. Lancet Neurol, 2016, 15: 270-278.
|
3. |
Patel A, Devinsky O, Cross JH, et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox‐Gastaut syndrome (LGS): results of a dose‐ranging, multi‐center, randomized, double‐blind, placebo‐controlled trial (GWPCARE3). Neurology, 2017, 89(3): e100.
|
4. |
Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 2018, 391(10125): 1085-1096.
|
5. |
Jones NA, Glyn SE, Akiyama S, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure, 2012, 21(5): 344-352.
|
6. |
Jones NA, Hill AJ, Smith I, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther, 2010, 332(2): 569-577.
|
7. |
Gofshteyn JS, Wilfong A, Devinsky O, et al. Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (fires) in the acute and chronic phases. J Child Neurol, 2017, 32(1): 35-40.
|
8. |
Hess EJ, Moody KA, Geffrey AL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia, 2016, 57(10): 1617-1624.
|
9. |
Toledo M, Beale R, Evans JS, et al. Long-term retention rates for antiepileptic drugs: a review of long-term extension studies and comparison with brivaracetam. Epilepsy Res, 2017, 138: 53-61.
|
10. |
Janssen Korea Ltd. An observational study to evaluate long-termretention rate of topiramate in participants with epilepsy, 2013. Available from https://clinicaltrials.gov/ct2/show/NCT01682681.
|
11. |
Gaston T, Szaflarski M, Hansen B, et al. Improvement in quality of life ratings after one year of treatment with pharmaceutical formulation of cannabidiol (CBD). Epilepsia, 2017, 58(suppl): 155.
|
12. |
Rosenberg EC, Louik J, Conway E, et al. Quality of life in childhood epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. Epilepsia, 2017, 58(8): e96-e100.
|
13. |
DeWolfe JL, Bebin EM, Cutter GR, et al. Effects of pharmaceutical grade cannabidiol on seizure frequency. American EpilepsySociety Abstracts Database (Abst. 2.100). Available from: https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/195499 Accessed May 7, 2018.
|
14. |
Gaston TE, Bebin EM, Cutter GR, et al. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia, 2017, 58(9): 1586-1592.
|
15. |
Sommerville K, Crockett J, Blakey GE, et al. Bidirectionaldrug-drug interaction with coadministration of cannabidiol andclobazam in a phase 1 healthy volunteer trial. American EpilepsySociety Abstracts Database (Abst. 1. 433). Available from: https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/381188 Accessed May 7, 2018.
|
16. |
Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology, 2018, 90(14): e1204-e1211.
|
17. |
Grayson L, Vines B, Nichol K, et al. An interaction between warfarin and cannabidiol, a casereport. Epilepsy Behav Case Rep, 2018, 9(2): 10-11.
|